Matches in SemOpenAlex for { <https://semopenalex.org/work/W2098095232> ?p ?o ?g. }
- W2098095232 endingPage "139" @default.
- W2098095232 startingPage "125" @default.
- W2098095232 abstract "Abstract Primary purpose. Low-grade lymphoproliferative disorders follow an indolent clinical course but are incurable with current therapy. Recently, three active agents for the treatment of these diseases have been identified: the purine analogs fludarabine, pentostatin and 2-chlorodeoxyadenosine. The purpose of this review is to summarize the current knowledge on the mechanism of action, clinical activity and toxicities of the purine analogs. Methods. Articles, abstracts and letters to the editor appearing in English literature and involving the use of the purine analogs in the treatment of hairy cell leukemia, chronic lymphocytic leukemia, indolent non-Hodgkin's lymphoma, cutaneous T cell lymphomas and Waldenström's macroglobulinemia were reviewed. Results and conclusion. Purine analogs have marked cytoreductive potential in the treatment of chronic lymphocytic leukemia, indolent non-Hodgkin's lymphoma and hairy cell leukemia. Major side effects include myelosuppression and infections. Profound lymphocytopenia can be sustained, predisposing patients to opportunistic infections. Although remissions achieved with these agents can be long-lasting, minimal residual disease frequently persists. Postremission strategies aimed at eradicating such microscopic diseases can potentially improve the results of purine analog therapy. Alternatively, the up-front combination of these agents with traditional chemotherapy may lead to higher response rates and more sustained remissions." @default.
- W2098095232 created "2016-06-24" @default.
- W2098095232 creator A5010337213 @default.
- W2098095232 creator A5015358498 @default.
- W2098095232 creator A5016346099 @default.
- W2098095232 date "1996-06-01" @default.
- W2098095232 modified "2023-10-14" @default.
- W2098095232 title "Purine Analogs for the Treatment of Low-Grade Lymphoproliferative Disorders" @default.
- W2098095232 cites W149140897 @default.
- W2098095232 cites W1494274243 @default.
- W2098095232 cites W1500755125 @default.
- W2098095232 cites W1513969749 @default.
- W2098095232 cites W1578697356 @default.
- W2098095232 cites W159981870 @default.
- W2098095232 cites W1605056933 @default.
- W2098095232 cites W1756818535 @default.
- W2098095232 cites W1779642901 @default.
- W2098095232 cites W1785340630 @default.
- W2098095232 cites W1786909711 @default.
- W2098095232 cites W1792577025 @default.
- W2098095232 cites W1797125879 @default.
- W2098095232 cites W1840080876 @default.
- W2098095232 cites W1848698181 @default.
- W2098095232 cites W1862276309 @default.
- W2098095232 cites W1890033097 @default.
- W2098095232 cites W1894269341 @default.
- W2098095232 cites W190170648 @default.
- W2098095232 cites W1906398149 @default.
- W2098095232 cites W1910475489 @default.
- W2098095232 cites W1917060610 @default.
- W2098095232 cites W1935154669 @default.
- W2098095232 cites W1944026430 @default.
- W2098095232 cites W1959866484 @default.
- W2098095232 cites W1970321630 @default.
- W2098095232 cites W1971245246 @default.
- W2098095232 cites W1978911289 @default.
- W2098095232 cites W1983066514 @default.
- W2098095232 cites W1987355545 @default.
- W2098095232 cites W1988783929 @default.
- W2098095232 cites W1990522636 @default.
- W2098095232 cites W1992227721 @default.
- W2098095232 cites W1999516176 @default.
- W2098095232 cites W2000812551 @default.
- W2098095232 cites W2004724254 @default.
- W2098095232 cites W2008734787 @default.
- W2098095232 cites W2012994890 @default.
- W2098095232 cites W2016807194 @default.
- W2098095232 cites W2023435229 @default.
- W2098095232 cites W2024446142 @default.
- W2098095232 cites W2025697028 @default.
- W2098095232 cites W2027719195 @default.
- W2098095232 cites W2038552887 @default.
- W2098095232 cites W2040178656 @default.
- W2098095232 cites W2052664886 @default.
- W2098095232 cites W2061331818 @default.
- W2098095232 cites W2074880157 @default.
- W2098095232 cites W2074930967 @default.
- W2098095232 cites W2079317120 @default.
- W2098095232 cites W2081409366 @default.
- W2098095232 cites W2084899812 @default.
- W2098095232 cites W2097778142 @default.
- W2098095232 cites W2154495833 @default.
- W2098095232 cites W2156374047 @default.
- W2098095232 cites W2161972520 @default.
- W2098095232 cites W2166014786 @default.
- W2098095232 cites W2176099867 @default.
- W2098095232 cites W218420279 @default.
- W2098095232 cites W2190576586 @default.
- W2098095232 cites W2218543073 @default.
- W2098095232 cites W2244683952 @default.
- W2098095232 cites W2267793562 @default.
- W2098095232 cites W2271724340 @default.
- W2098095232 cites W2278012184 @default.
- W2098095232 cites W2292664782 @default.
- W2098095232 cites W2294296527 @default.
- W2098095232 cites W2296484683 @default.
- W2098095232 cites W2314659489 @default.
- W2098095232 cites W2317201497 @default.
- W2098095232 cites W2332209737 @default.
- W2098095232 cites W2335457765 @default.
- W2098095232 cites W2340740779 @default.
- W2098095232 cites W2414892177 @default.
- W2098095232 cites W2442079786 @default.
- W2098095232 cites W2462245305 @default.
- W2098095232 cites W2474959262 @default.
- W2098095232 cites W2916663880 @default.
- W2098095232 cites W4232231972 @default.
- W2098095232 cites W4233161682 @default.
- W2098095232 cites W4235838915 @default.
- W2098095232 cites W4239548556 @default.
- W2098095232 cites W4240037281 @default.
- W2098095232 cites W4243872435 @default.
- W2098095232 cites W4252269941 @default.
- W2098095232 cites W4253033861 @default.
- W2098095232 cites W65919465 @default.
- W2098095232 cites W794203970 @default.
- W2098095232 doi "https://doi.org/10.1634/theoncologist.1-3-125" @default.
- W2098095232 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10387979" @default.